- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
- Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
- Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
- Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
- Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
More ▼
Key statistics
As of last trade Mirum Pharmaceuticals Inc (MIRM:NMQ) traded at 24.70, 6.74% above its 52-week low of 23.14, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.60 |
---|---|
High | 24.77 |
Low | 24.07 |
Bid | 24.70 |
Offer | 24.83 |
Previous close | 24.96 |
Average volume | 628.52k |
---|---|
Shares outstanding | 47.13m |
Free float | 45.96m |
P/E (TTM) | -- |
Market cap | 1.13bn USD |
EPS (TTM) | -3.82 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 16:03 BST.
More ▼